

Medical News

Public Affairs and Media Relations

614-293-3737



Media Contact:

Amanda J. Harper
OSUCCC – James Media Relations
614-685-5420
Amanda.Harper2@osumc.edu

CAR-T Immunotherapy Now Approved for Certain Adult Lymphoma Patients

COLUMBUS, Ohio – The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced [lymphoma](#). The therapy uses a patient’s own white blood cells, which are modified in a lab and re-trained to recognize specific markers on the surface of the cell and then target and kill only those cancerous cells.

“This is truly a living therapy. It’s a patient’s own cells that are reinfused and go to work fighting cancer,” said [Samantha Jaglowski](#), MD, MPH, a hematologist at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), who tested the therapy in [clinical trials](#). “This is really the epitome of personalized medicine.”

Clinical trial data showed that more than half of patients who had failed at least two rounds of [chemotherapy](#) or a stem cell treatment responded to CAR-T treatment.

“For these patients, the rate of success in the next line of treatment is about 26 percent, and the average overall survival is about six months,” said Jaglowski. “But with CAR-T, the response rate is nearly 60 percent, and the average survival rate of those patients is yet to be seen. Patients who have success with this therapy tend to stay in remission.”

Jaglowski notes that CAR-T tends to work quickly, with many patients achieving complete remission with a few months and often with fewer side effects than traditional cancer treatments such as chemotherapy and [radiation](#).

The OSUCCC – James is the only cancer treatment center in Ohio currently offer CAR-T therapy and is one of only a handful of centers across the country. The therapy was also FDA-approved for a rare type of treatment-resistant childhood leukemia in July.

To learn more about CAR-T and clinical trials at the OSUCCC – James, visit cancer.osu.edu/cart or call 1-800-293-8066.

About the OSUCCC – James

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of 48 National Cancer Institute-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program's 308-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by *U.S. News & World Report* and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, visit cancer.osu.edu.